{"id":22,"date":"2012-08-05T23:13:35","date_gmt":"2012-08-05T23:13:35","guid":{"rendered":"http:\/\/medchem101.com\/?page_id=22"},"modified":"2019-02-01T15:42:50","modified_gmt":"2019-02-01T20:42:50","slug":"past-projects","status":"publish","type":"page","link":"https:\/\/medchem101.com\/?page_id=22","title":{"rendered":"Past Projects"},"content":{"rendered":"

\"\"The following nonconfidential brief project summaries are presented below to
\ndemonstrate just a few of the various types of projects that our scientists have
\nsuccessfully completed.<\/span><\/strong><\/p>\n

 <\/p>\n

 <\/p>\n

Leukotriene B4<\/sub> (LTB4<\/sub>) Antagonist<\/strong><\/p>\n

Developed a novel series of LTB4<\/sub> receptor antagonists for an academic client using a structure based approach. Developed fluorescent-labeled ligand. NIH SBIR funded. One paper published1<\/sup>.<\/p>\n

\"\"<\/a><\/p>\n

    \n
  1. D. Kiel et al. Adv. Prostaglandin Thromboxane Leukot.<\/em> 1991 21A<\/strong>:403<\/li>\n<\/ol>\n

     <\/p>\n

    Cannabinoid CB2 antagonist<\/strong><\/p>\n

    Developed a novel series of CB2 antagonists with an academic collaborator using a structure-based approach.<\/p>\n

    \"\"<\/p>\n

     <\/p>\n

    Glucosyl-Ceramide Synthase Inhibitor<\/strong><\/p>\n

    Carried out SAR studies on lead compound with an academic collaborator. New potent analog developed.<\/p>\n

    Project was NIH SBIR funded. \u00a0One paper published1<\/sup>.\u00a0One patent issued2<\/sup>.\u00a0Resulted in Pharma company licensing deal.<\/p>\n

    \"\"<\/p>\n

      \n
    1. A. Abe et al. J. Lipid Res.<\/em> 1995 36<\/strong>:611<\/li>\n
    2. US 5,916,911 (1999)<\/li>\n<\/ol>\n

       <\/p>\n

       <\/p>\n

      Sirt1 Activator<\/strong><\/p>\n

      Discovered a natural product Sirt1 activator (resveratrol) as potential lifespan extension agent employing a natural products-based screening approach.\u00a0 Carried out SAR studies on lead compound.\u00a0 Two papers published1,2<\/sup>. Patents issued3<\/sup>. Resulted in Pharma company licensing deal.<\/p>\n

      \"\"<\/p>\n

        \n
      1. KT Howitz et al. Nature<\/em> 2003 425<\/strong>:191<\/li>\n
      2. H Yang et al. Aging Cell<\/em> 2007 6<\/strong>:35<\/li>\n
      3. US 7,544,497 (2009)<\/li>\n<\/ol>\n

         <\/p>\n

        Discovery of Novel Endogenous Lipid Mediators<\/strong><\/p>\n

        Synthesized new lipids related to anandamide to confirm structure of endogenous mediators and ligands with academic collaborator. Discovered new target for anti-inflammatory analgesic drug development. Three papers published1-3<\/sup>. One patent issued4<\/sup>.<\/p>\n

        \"\"<\/p>\n

          \n
        1. SM Huang et al. J. Biol. Chem.<\/em> 2001 276<\/strong>:42639<\/li>\n
        2. CJ Chu et al. J. Biol. Chem.<\/em> 2003 278<\/strong>:13633<\/li>\n
        3. SH Burstein et al. Bioorg. Med. Chem.<\/em> 2007 15<\/strong>:3345<\/li>\n
        4. US 7,544,714 (2009)<\/li>\n<\/ol>\n

           <\/p>\n

          Sphingosine Kinase-1 Inhibitor<\/strong><\/p>\n

          Designed and synthesized novel series of Sphingosine Kinase-1 inhibitors as potential anticancer agents using structure-based approach with academic collaborator. Two papers published1,2<\/sup>. One patent issued3<\/sup>.\u00a0 Resulted in Pharma company licensing deal.<\/p>\n

          \"\"<\/p>\n

            \n
          1. SW Paugh et al. Blood 2008 112<\/strong>:1382<\/li>\n
          2. D Kapitonov et al. Cancer Res. 2009 69<\/strong>:6915<\/li>\n
          3. US 8,314,151 (2012)<\/li>\n<\/ol>\n

             <\/p>\n

            GPR55 Receptor Deorphaning<\/strong><\/p>\n

            Designed and synthesized potential endogenous ligands for GPR55 with academic collaborator. Project is on-going.<\/p>\n

             <\/p>\n","protected":false},"excerpt":{"rendered":"

            The following nonconfidential brief project summaries are presented below to demonstrate just a few of the various types of projects that our scientists have successfully completed.     Leukotriene B4 (LTB4) Antagonist Developed a novel series of LTB4 receptor antagonists for an academic client using a structure based approach. Developed fluorescent-labeled ligand. NIH SBIR funded. … <\/p>\n

            Continue reading “Past Projects”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full-width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/medchem101.com\/index.php?rest_route=\/wp\/v2\/pages\/22"}],"collection":[{"href":"https:\/\/medchem101.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medchem101.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medchem101.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medchem101.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22"}],"version-history":[{"count":38,"href":"https:\/\/medchem101.com\/index.php?rest_route=\/wp\/v2\/pages\/22\/revisions"}],"predecessor-version":[{"id":482,"href":"https:\/\/medchem101.com\/index.php?rest_route=\/wp\/v2\/pages\/22\/revisions\/482"}],"wp:attachment":[{"href":"https:\/\/medchem101.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}